Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.

Humans COVID-19 Vaccines BNT162 Vaccine COVID-19 / prevention & control CD8-Positive T-Lymphocytes Australia / epidemiology SARS-CoV-2 Immunoglobulin G Antibodies, Neutralizing Immunity Antibodies, Viral Vaccination

Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
06 2023
Historique:
received: 29 09 2022
accepted: 10 04 2023
medline: 2 6 2023
pubmed: 30 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, including neutralizing antibodies, receptor-binding domain (RBD) antibodies, SARS-CoV-2 spike-specific B cells, and CD4

Identifiants

DOI: 10.1038/s41590-023-01508-y PMID: 37248417 PMC: PMC10232372
pubmed: 37248417
doi: 10.1038/s41590-023-01508-y
pii: 10.1038/s41590-023-01508-y
pmc: PMC10232372
doi:

Substances chimiques

COVID-19 Vaccines 0
BNT162 Vaccine 0
Immunoglobulin G 0
Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

966-978

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI136514
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI150747
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. The Author(s).

Références

The Lancet Self-determination and Indigenous health. Lancet 396, 361 (2020).
pubmed: 32771091 doi: 10.1016/S0140-6736(20)31682-2
Kaplan, H. S. et al. Voluntary collective isolation as a best response to COVID-19 for indigenous populations? A case study and protocol from the Bolivian Amazon. Lancet 395, 1727–1734 (2020).
pubmed: 32422124 pmcid: 7228721 doi: 10.1016/S0140-6736(20)31104-1
Arias, E., Tejada-Vera, B., Kochanek, K. D. & Ahmad, F. B. Provisional Life Expectancy Estimates for 2021. Vital Statistics Rapid Release Report No. 23 (National Center for Health Statistics, 2022).
Mallard, A., Pesantes, M. A., Zavaleta-Cortijo, C. & Ward, J. An urgent call to collect data related to COVID-19 and Indigenous populations globally. BMJ Glob. Health 6, e004655 (2021).
pubmed: 33653731 doi: 10.1136/bmjgh-2020-004655
Kochanek, K., Murphy, S., Xu, J. & Arias, E. Deaths: final data for 2017. Natl Vital Stat. Rep. 68, 1–77 (2019).
pubmed: 32501199
Tollefson, D. et al. Burden of tuberculosis in indigenous peoples globally: a systematic review. Int. J. Tuberc. Lung Dis. 17, 1139–1150 (2013).
pubmed: 23823137 doi: 10.5588/ijtld.12.0385
Davis, J. S. et al. Sepsis in the tropical Top End of Australia’s Northern Territory: disease burden and impact on Indigenous Australians. Med. J. Aust. 194, 519–524 (2011).
pubmed: 21644899 doi: 10.5694/j.1326-5377.2011.tb03088.x
Li-Kim-Moy, J. et al. Australian vaccine preventable disease epidemiological review series: influenza 2006 to 2015. Commun. Dis. Intell. Q Rep. 40, E482–E495 (2016).
pubmed: 28043223
Markey, P., Su, J.-Y., Wattiaux, A., Trauer, J. & Krause, V. H1N1 2009 pandemic influenza in Indigenous Australians. Microbiol. Aust. 32, 36–38 (2011).
doi: 10.1071/MA11036
Lenzi, L., Mello, Â. M., Silva, L. R., Grochocki, M. H. & Pontarolo, R. Pandemic influenza A (H1N1) 2009: risk factors for hospitalization. J. Bras. Pneumol. 38, 57–65 (2012).
pubmed: 22407041 doi: 10.1590/S1806-37132012000100009
Centers for Disease Control and Prevention Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives—12 states, 2009. MMWR Morb. Mortal. Wkly Rep. 58, 1341–1344 (2009).
Verrall, A. et al. Hospitalizations for pandemic (H1N1) 2009 among Maori and Pacific Islanders, New Zealand. Emerg. Infect. Dis. 16, 100–102 (2010).
pubmed: 20031050 pmcid: 2874371 doi: 10.3201/eid1601.090994
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246 doi: 10.1056/NEJMoa2034577
Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572–577 (2021).
pubmed: 34044428 doi: 10.1038/s41586-021-03653-6
Mudd, P. A. et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell 185, 603–613 (2022).
pubmed: 35026152 doi: 10.1016/j.cell.2021.12.026
Minervina, A. A. et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8
pubmed: 35383307 pmcid: 9106845 doi: 10.1038/s41590-022-01184-4
Kedzierska, K. & Thomas, P. G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep. Med. 3, 100562 (2022).
pubmed: 35474748 pmcid: 8872824 doi: 10.1016/j.xcrm.2022.100562
Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).
pubmed: 34648302 pmcid: 9284784 doi: 10.1126/science.abm0829
Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).
pubmed: 32398876 pmcid: 8183627 doi: 10.1038/s41591-020-0913-5
Mahan, A. E. et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog. 12, e1005456 (2016).
pubmed: 26982805 pmcid: 4794126 doi: 10.1371/journal.ppat.1005456
Wang, J.-R. et al. Glycomic signatures on serum IgGs for prediction of postvaccination response. Sci. Rep. 5, 7648 (2015).
pubmed: 25612906 pmcid: 4303884 doi: 10.1038/srep07648
McLean, M. R. et al. Serological and cellular inflammatory signatures in end-stage kidney disease and latent tuberculosis. Clin. Transl. Immunol. 10, e1355 (2021).
doi: 10.1002/cti2.1355
Herati, R. S. et al. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat. Immunol. 23, 1183–1192 (2022).
pubmed: 35902637 pmcid: 9880663 doi: 10.1038/s41590-022-01274-3
Kedzierska, K. & Nguyen, T. H. O. PD-1 blockade unblocks immune responses to vaccination. Nat. Immunol. 23, 1135–1137 (2022).
pubmed: 35902636 doi: 10.1038/s41590-022-01254-7
Koutsakos, M. et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep. Med. 2, 100208 (2021).
pubmed: 33564749 pmcid: 7862905 doi: 10.1016/j.xcrm.2021.100208
Selva, K. J. et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat. Commun. 12, 2037 (2021).
pubmed: 33795692 pmcid: 8016934 doi: 10.1038/s41467-021-22236-7
Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162 (2021).
pubmed: 33608522 pmcid: 7896046 doi: 10.1038/s41467-021-21444-5
Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26, 453–455 (2020).
pubmed: 32284614 pmcid: 7095036 doi: 10.1038/s41591-020-0819-2
Nguyen, T. H. O. et al. CD8
pubmed: 33951417 pmcid: 8049468 doi: 10.1016/j.immuni.2021.04.009
Rowntree, L. C. et al. SARS-CoV-2-specific T cell memory with common TCRαβ motifs is established in unvaccinated children who seroconvert after infection. Immunity 55, 1299–1315 (2022).
pubmed: 35750048 pmcid: 9174177 doi: 10.1016/j.immuni.2022.06.003
Habel, J. R. et al. Suboptimal SARS-CoV-2-specific CD8
pubmed: 32913053 pmcid: 7533701 doi: 10.1073/pnas.2015486117
Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8
pubmed: 33184509 doi: 10.1038/s41591-020-01143-2
Rowntree, L. C. et al. SARS-CoV-2-specific CD8
pubmed: 34086357 pmcid: 8242669 doi: 10.1111/imcb.12482
Ferretti, A. P. et al. Unbiased screens show CD8
pubmed: 33128877 pmcid: 7574860 doi: 10.1016/j.immuni.2020.10.006
La Gruta, N. L. et al. Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J. Clin. Invest. 120, 1885–1894 (2010).
pubmed: 20440073 pmcid: 2877949 doi: 10.1172/JCI41538
Clemens, E. B. et al. Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Immunol. Cell Biol. 94, 367–377 (2016).
pubmed: 26493179 doi: 10.1038/icb.2015.93
van de Sandt, C. E. et al. Challenging immunodominance of influenza-specific CD8
pubmed: 31811120 pmcid: 6898063 doi: 10.1038/s41467-019-13346-4
Ndhlovu, Z. M. et al. Magnitude and kinetics of CD8
pubmed: 26362266 pmcid: 4575777 doi: 10.1016/j.immuni.2015.08.012
Shomuradova, A. S. et al. SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity 53, 1245–1257 (2020).
pubmed: 33326767 pmcid: 7664363 doi: 10.1016/j.immuni.2020.11.004
Kim, M. L. et al. Dysregulated IL-1β-GM-CSF axis in acute rheumatic fever that is limited by hydroxychloroquine. Circulation 138, 2648–2661 (2018).
pubmed: 30571257 doi: 10.1161/CIRCULATIONAHA.118.033891
Russell, M. L. et al. Combining genotypes and T cell receptor distributions to infer genetic loci determining V(D)J recombination probabilities. eLife 11, e73475 (2022).
pubmed: 35315770 pmcid: 8940181 doi: 10.7554/eLife.73475
Yu, X. et al. Profiling IgG N-glycans as potential biomarker of chronological and biological ages: a community-based study in a Han Chinese population. Medicine 95, e4112 (2016).
pubmed: 27428197 pmcid: 4956791 doi: 10.1097/MD.0000000000004112
Koutsakos, M. et al. Circulating T
pubmed: 29444980 doi: 10.1126/scitranslmed.aan8405
Bange, E. M. et al. CD8
pubmed: 34017137 pmcid: 8291091 doi: 10.1038/s41591-021-01386-7
Habel, J. R. et al. HLA-A*11:01-restricted CD8
pubmed: 35255101 pmcid: 8929706 doi: 10.1371/journal.ppat.1010337
Hensen, L. et al. CD8
pubmed: 34006841 pmcid: 8132304 doi: 10.1038/s41467-021-23212-x
Zhao, Y., Zhang, X., Foley, M. & Guthridge, S. Northern Territory Burden of Disease Study: Fatal Burden of Disease and Injury, 2004–2013 (Department of Health, 2016).
Nous Group. Evaluation of the Northern Territory Chronic Conditions Prevention and Management Strategy 2010-2020: Final Report (Northern Territory Department of Health, 2020).
Hare, M. J. L. et al. Prevalence and incidence of diabetes among Aboriginal people in remote communities of the Northern Territory, Australia: a retrospective, longitudinal data-linkage study. BMJ Open 12, e059716 (2022).
pubmed: 35569825 pmcid: 9125760 doi: 10.1136/bmjopen-2021-059716
Li, L. et al. Estimating the total prevalence and incidence of end-stage kidney disease among Aboriginal and non-Aboriginal populations in the Northern Territory of Australia, using multiple data sources. BMC Nephrol. 19, 15 (2018).
pubmed: 29334912 pmcid: 5769509 doi: 10.1186/s12882-017-0791-3
Zhang, E. et al. Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments. Gut, https://doi.org/10.1136/gutjnl-2022-329136 (2023).
doi: 10.1136/gutjnl-2022-329136 pubmed: 37015751
Rowntree, L. C. et al. Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. Clin. Transl. Immunology 10, e1258 (2021).
pubmed: 33680466 pmcid: 7916820 doi: 10.1002/cti2.1258
Zhang, W. et al. SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. Nat. Commun. 13, 2774 (2022).
pubmed: 35589689 pmcid: 9120039 doi: 10.1038/s41467-022-30088-y
Caly, L. et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. 212, 459–462 (2020).
pubmed: 32237278 pmcid: 7228321 doi: 10.5694/mja2.50569
Di Pietro, A. et al. Targeting BMI-1 in B cells restores effective humoral immune responses and controls chronic viral infection. Nat. Immunol. 23, 86–98 (2022).
pubmed: 34845392 doi: 10.1038/s41590-021-01077-y
Valkenburg, S. A. et al. Molecular basis for universal HLA-A*0201-restricted CD8
pubmed: 27036003 pmcid: 4843436 doi: 10.1073/pnas.1603106113
Nguyen, T. H. et al. Understanding CD8
pubmed: 28435676 pmcid: 5382434 doi: 10.1038/cti.2017.4
Brunson, J. C. & Read, Q. D. ggalluvial: Alluvial Plots in ‘ggplot2’. R package version 0.12.3 https://cran.r-project.org/web/packages/ggalluvial/index.html#:~:text=ggalluvial%3A%20Alluvial%20Plots%20in%20'ggplot2,%3Cdoi%3A10.1109%2FINFVIS (2020).
Dash, P. et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature 547, 89–93 (2017).
pubmed: 28636592 pmcid: 5616171 doi: 10.1038/nature22383
Mayer-Blackwell, K. et al. TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs. eLife 10, e68605 (2021).
pubmed: 34845983 pmcid: 8631793 doi: 10.7554/eLife.68605
Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 26, 1428–1434 (2020).
pubmed: 32661393 doi: 10.1038/s41591-020-0995-0
R Core Team. R: A language and environment for statistical computing (R Foundation for Statistical Computing, 2022).
Revelle, W. psych: Procedures for psychological, psychometric, and personality research. R package version 2.2.5 https://CRAN.R-project.org/package=psych (2022).
Kassambara, A. rstatix: Pipe-friendly framework for basic statistical tests. R package version 0.7.0 https://cran.r-project.org/web/packages/rstatix/index.html (2021).
Wei, T. & Simko, V. corrplot: Visualization of a correlation matrix. R package version 0.92 https://cran.r-project.org/web/packages/corrplot/corrplot.pdf (2021).
Blighe, K., Rana, S. & Lewis, M. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. R package version 1.14.0 https://bioconductor.org/packages/devel/bioc/vignettes/EnhancedVolcano/inst/doc/EnhancedVolcano.html (2022).

Auteurs

Wuji Zhang (W)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0001-7460-4956

Lukasz Kedzierski (L)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, Victoria, Australia.
ORCID: 0000-0003-0203-1057

Brendon Y Chua (BY)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Mark Mayo (M)

Menzies School of Health Research, Darwin, Northern Territory, Australia.

Claire Lonzi (C)

Menzies School of Health Research, Darwin, Northern Territory, Australia.

Vanessa Rigas (V)

Menzies School of Health Research, Darwin, Northern Territory, Australia.

Bianca F Middleton (BF)

Menzies School of Health Research, Darwin, Northern Territory, Australia.

Hayley A McQuilten (HA)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0002-7089-5300

Louise C Rowntree (LC)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Lilith F Allen (LF)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Ruth A Purcell (RA)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0001-6378-5114

Hyon-Xhi Tan (HX)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0003-1064-3934

Jan Petersen (J)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Priyanka Chaurasia (P)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
ORCID: 0000-0002-3755-159X

Francesca Mordant (F)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0002-3754-2642

Mikhail V Pogorelyy (MV)

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Anastasia A Minervina (AA)

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Jeremy Chase Crawford (JC)

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
ORCID: 0000-0003-4096-6048

Griffith B Perkins (GB)

Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
ORCID: 0000-0001-8559-5872

Eva Zhang (E)

Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Macquarie University, Sydney, New South Wales, Australia.

Stephanie Gras (S)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia.
ORCID: 0000-0001-7416-038X

E Bridie Clemens (EB)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.

Jennifer A Juno (JA)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0002-9072-1017

Jennifer Audsley (J)

Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

David S Khoury (DS)

Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
ORCID: 0000-0002-2663-1551

Natasha E Holmes (NE)

Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.

Irani Thevarajan (I)

Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Services, Royal Melbourne Hospital and Doherty Department, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Kanta Subbarao (K)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
World Health Organization Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Florian Krammer (F)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID: 0000-0003-4121-776X

Allen C Cheng (AC)

Department of Infectious Diseases, Alfred Hospital and Central Clinical School and School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Monash Infectious Diseases, Monash Health and School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.

Miles P Davenport (MP)

Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
ORCID: 0000-0002-4751-1831

Branka Grubor-Bauk (B)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.

P Toby Coates (PT)

Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.

Britt Christensen (B)

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.

Paul G Thomas (PG)

Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
ORCID: 0000-0001-7955-0256

Adam K Wheatley (AK)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0002-5593-9387

Stephen J Kent (SJ)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, Victoria, Australia.
Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
ORCID: 0000-0002-8539-4891

Jamie Rossjohn (J)

Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
ORCID: 0000-0002-2020-7522

Amy W Chung (AW)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
ORCID: 0000-0003-0020-9704

John Boffa (J)

Central Australian Aboriginal Congress, Alice Springs, Northern Territory, Australia.

Adrian Miller (A)

Indigenous Engagement, CQUniversity, Townsville, Queensland, Australia.

Sarah Lynar (S)

Menzies School of Health Research, Darwin, Northern Territory, Australia.
Infectious Diseases Department, Royal Darwin Hospital and Northern Territory Medical Programme, Darwin, Northern Territory, Australia.

Jane Nelson (J)

Menzies School of Health Research, Darwin, Northern Territory, Australia.

Thi H O Nguyen (THO)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia. tho.nguyen@unimelb.edu.au.
ORCID: 0000-0002-9294-7693

Jane Davies (J)

Menzies School of Health Research, Darwin, Northern Territory, Australia. jane.davies@menzies.edu.au.
ORCID: 0000-0002-3843-837X

Katherine Kedzierska (K)

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia. kkedz@unimelb.edu.au.
Center for Influenza Disease and Emergence Response, Melbourne, Victoria, Australia. kkedz@unimelb.edu.au.
ORCID: 0000-0001-6141-335X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Robust and prototypical immune responses...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Robust and prototypical immune responses...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Robust and prototypical immune responses...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Robust and prototypical immune responses...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Robust and prototypical immune responses...
questionsmedicales.fr › Régions géographiques › Océanie › Australasie › Australie › Robust and prototypical immune responses...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Robust and prototypical immune responses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Robust and prototypical immune responses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Robust and prototypical immune responses...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Robust and prototypical immune responses...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Robust and prototypical immune responses...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Robust and prototypical immune responses...